Estrella Immunopharma Inc
For the period ended Jun 30, 2024. Filed Sep 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Sep 27, 2024
ESLA$0.51+36.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
Index to Financial Statement
| Report of Independent Registered Public Accounting Firm (Macias Gini and O’Connell LLP, PCAOB ID 324) | F-2 |
|---|---|
| Report of Independent Registered Public Accounting Firm (Marcum LLP, PCAOB ID 688) | F-3 |
| Consolidated Financial Statements | |
| Consolidated Balance Sheets | F-4 |
| Consolidated Statements of Operations | F-5 |
| Consolidated Statements of Changes in Stockholders’ Equity (Deficit) | F-6 |
| Consolidated Statements of Cash Flows | F-7 |
| Notes to Consolidated Financial Statements | F-8 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.